OncoEthix brings in CHF18m to push ex-Mitsubishi candidate
This article was originally published in Scrip
OncoEthix, a Swiss-based biotech firm focused on drug development in oncology, has closed a series B financing which raised CHF18m (around $19m). SV Life Sciences (SVLS) led the financing, joined by new investor Edmond de Rothschild Investment Partners. Existing investors including Index Ventures and Endeavour Vision also participated.